1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole | 170632-42-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole
• 英文别名: 5-(1′-benzyl-1H-indazol-3′-yl)furan-2-carboxylic acid；1-Benzyl-3-(5''-hydroxycarbonylfuryl)-indazole；1-benzyl-3-(5-hydroxycarbonyl-2-furyl)-1H-indazole；1-benzyl-3-(5-carboxy-2-furyl)indazole；5-(1-benzylindazol-3-yl)furan-2-carboxylic acid
• CAS: 170632-42-5
• 化学式: C₁₉H₁₄N₂O₃
• 分子量: 318.332
• InChiKey: ZSMDXWFFIQRLLR-UHFFFAOYSA-N

物化性质

• 熔点：
  202-203 °C
• 沸点：
  575.0±50.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole 在 氯化亚砜 作用下， 以 苯 为溶剂， 生成 1-benzyl-3-(5-chlorocarbonyl-furan-2-yl)indazole
  参考文献：
  名称：

  Pyrazole derivatives, their preparation and their use in pharmaceuticals

  摘要：

  本发明涉及式I的吡唑衍生物，其制备及其在药物中的应用：##STR1## 其中X，R.sup.1，R.sup.1a，R.sup.2，R.sup.3，R.sup.4和n如索引中所定义，它们是有用的药用活性化合物，用于治疗和预防疾病，例如心血管疾病，如高血压，心绞痛，心力衰竭，血栓或动脉粥样硬化。式I的化合物能够调节体内环鸟苷酸单磷酸鸟苷“cGMP”的产生，并通常适用于与扰乱cGMP平衡相关的疾病的治疗和预防。该发明还涉及制备式1的化合物的方法，它们用于治疗和预防上述疾病，以及用于为此目的制备药物，以及包含式I化合物的药物制剂。

  公开号：

  US06162819A1
• 作为产物：
  描述：

  5-苯甲酰基呋喃-2-甲酸甲酯 在 sodium hydroxide 、 三氟化硼乙醚 、 溶剂黄146 作用下， 生成 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole
  参考文献：
  名称：

  Synthesis of 1-Benzyl-3-(5‘-hydroxymethyl-2‘-furyl)indazole Analogues as Novel Antiplatelet Agents

  摘要：

  1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (28, YC-1) was selected as the lead compound for systemic structural modification. After screening for antiplatelet activity, SARs of YC-1 analogues were established. Among these potent active derivatives, compounds 29, 30, 31, 44, and 45 functioned as potent activators of sGC and inhibitors of PDE5 with potency comparable to that of YC-1. In addition, compound 58 was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation.

  DOI：

  10.1021/jm010001h

文献信息

• Method of treating disorders related to protease-activated receptors-induced cell activation
  申请人：——

  公开号：US20020004518A1

  公开（公告）日：2002-01-10

  A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

  一种治疗与蛋白酶激活受体引起的细胞活化相关障碍的方法。该方法包括向需要的受试者施用具有吡唑基核的化合物；通过烷基连接剂与吡唑基核的1-N键合的芳基团；在吡唑基核的4-C和5-C处融合的第二个芳基团；以及直接与吡唑基核的3-C键合的第三个芳基团。
• Pyrazole derivatives, their preparation and their use in pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06162819A1

  公开（公告）日：2000-12-19

  The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: ##STR1## in which X, R.sup.1, R.sup.1a, R.sup.2, R.sup.3, R.sup.4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate "cGMP" and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula 1, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.

  本发明涉及式I的吡唑衍生物，其制备及其在药物中的应用：##STR1## 其中X，R.sup.1，R.sup.1a，R.sup.2，R.sup.3，R.sup.4和n如索引中所定义，它们是有用的药用活性化合物，用于治疗和预防疾病，例如心血管疾病，如高血压，心绞痛，心力衰竭，血栓或动脉粥样硬化。式I的化合物能够调节体内环鸟苷酸单磷酸鸟苷“cGMP”的产生，并通常适用于与扰乱cGMP平衡相关的疾病的治疗和预防。该发明还涉及制备式1的化合物的方法，它们用于治疗和预防上述疾病，以及用于为此目的制备药物，以及包含式I化合物的药物制剂。
• The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents
  作者：Juan Xiao、Chunmei Jin、Zhixue Liu、Shujing Guo、Xiaochuan Zhang、Xin Zhou、Xue Wu

  DOI：10.1039/c5ob00710k

  日期：——

  YC-1and its derivatives have been demonstrated for the first time with significant effects on inhibiting LX-2 cell activation and inducing apoptosis of LX-2 cells, making them potential agents for hepatic fibrosis therapy.

  YC-1及其衍生物首次被证明具有显著抑制LX-2细胞活化和诱导LX-2细胞凋亡的作用，使它们成为潜在的肝纤维化治疗药物。
• Blockade of voltage dependent sodium channels
  申请人：——

  公开号：US20030171403A1

  公开（公告）日：2003-09-11

  Compounds of formula (1), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

  式（1）的化合物及其药学上可接受的盐能够阻断电压依赖性钠通道，并且在治疗青光眼和多发性硬化症方面具有用处。
• [EN] BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS<br/>[FR] BLOCAGE DE CANAUX SODIQUES DEPENDANT DE LA TENSION
  申请人：UNIV LONDON

  公开号：WO2001057024A1

  公开（公告）日：2001-08-09

  Compounds of formula (I), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

  式(I)的化合物及其药学上可接受的盐，能够阻断电压依赖性钠通道，特别适用于治疗青光眼和多发性硬化症。